Efficacious but insidious: A retrospective analysis of fludarabine induced myelotoxicity using long term culture initiating cells in 100 follicular lymphoma patients

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	JANÍKOVÁ Andrea KOŘÍSTEK Zdeněk VINKLÁRKOVÁ Jaroslava PAVLÍK Tomáš ŠTÍCHA Michal NAVRÁTIL Milan KRÁL Zdeněk VÁŠOVÁ Ingrid MAYER Jiří
Year of publication	2009
Type	Article in Periodical
Magazine / Source	Experimental Hematology
MU Faculty or unit	Faculty of Medicine
Citation
Field	Oncology and hematology
Keywords	NON-HODGKIN-LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; BLOOD PROGENITOR CELLS; ACUTE MYELOID-LEUKEMIA; PREVIOUSLY UNTREATED PATIENTS; IV INDOLENT LYMPHOMA; HIGH-DOSE THERAPY; BONE-MARROW; PHASE-II
Description	Fludarabine has been recognized as effective treatment in patients with follicular lymphoma (FL), but can induce myelotoxicity of unknown mechanism. Fludarabine and procarbazine have a dramatic influence, especially on the most immature hematopoietic cells, mirrored in reduced numbers of LTC-IC. This finding is consistent with clinical observations (poor mobilization after fludarabine) and offers an insight into the mechanism of fludarabine-induced myelotoxicity.
Related projects:	Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies